Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies

NCT04949737 | Recruiting

• 2 other identifiers: 20_RIPH2_222020-A02412-37
• Study Type: observational
• Target: 112
• Locations: 1 country
• Sites: 1

Brief Summary

Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers in the West-Indies will help to understand the epidemiology of this cancer, which is over-incident in the West Indies compared to France. In addition, the constitution of a biobank (tumor tissues, healthy tissues and serum) will allow to set up in a second time etiological studies to identify other risk factors in particular in connection with the exposure to environmental pollutants to adapt the prevention measures.

Conditions

Stomach Neoplasms; Gastric Neoplasms; Helicobacter Pylori

Keywords

Helicobacter Pylori; Gastric cancer; Prevalence; French West-Indies

Outcome Measures

Primary Outcomes (1)

• Estimation of the prevalence of Helicobacter pylori

  Helicobacter Pylori has detected by immunohistochemistry in the stomach of patients with gastric cancer.

  At baseline

Study Arms (1)

Helicobacter Pylori detection

Systematic biopsies of the tumor and the gastric cavity will be performed during the initial fibroscopy in accordance with the recommendations of the French Society of Digestive Endoscopy (SFED).

Biological: Helicobacter Pylori detection

Interventions

Helicobacter Pylori detection BIOLOGICAL

Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup. Additional data will be collected through a questionnaire.

Helicobacter Pylori detection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Eligible patients (with a suspected endoscopic diagnosis of gastric cancer) will be selected either at the Martinique University Hospital or at the Sainte-Marie clinic during consultations or hospitalizations.

You may qualify if:

• Patient over 18 years of age, residing for at least 6 months in Martinique, with a primary diagnosis of gastric cancer
• Patient having read the information note and having signed the consent to participate in the study
• Patient with social security coverage

You may not qualify if:

• Refusal to participate
• Patient who could not answer the questionnaires
• Patient not affiliated to a social security system
• Patient not fluent in French
• Patient under legal protection (legal protection, guardianship, curators, etc.)

Sponsors & Collaborators

• University Hospital Center of Martinique: lead

Study Sites (1)

CHU Martinique

Fort-de-France, 97261, Martinique

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Samples retained for extraction of DNA from whole blood

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Clarisse JOACHIM-CONTARET

  CHU Martinique

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Clarisse JOACHIM-CONTARET

CONTACT

+596596559674; clarisse.joachim@chu-martinique.fr

Mickaelle ROSE

CONTACT

+596596592623; mickaelle.rose@chu-martinique.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 16, 2021
• First Posted: July 2, 2021
• Study Start: October 9, 2025
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: March 31, 2026

Record last verified: 2026-03

Locations

MA (1)